As Quantity Of Cannabis IND Applications Grows, US FDA Has ‘Quality Considerations’ Guidance

 
• By Malcolm Spicer

Research targeting botanicals generally, as well as cannabis, as potential APIs is increasing, a factor in CDER’s publication of cannabis trials guidance, the FDA’s Norman Birenbaum says in an interview.

The FDA is trying to create standards for safe use of hemp and cannabis-related ingredients while still maintaining access to the products. • Source: Nielsen Hobbs; the Pink Sheet | Shutterstock, FDA images

More from Approval Standards

More from Pathways & Standards